CLRB
Price:
$2.08
Market Cap:
$74.57M
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC p...[Read more]
Industry
Biotechnology
IPO Date
2005-11-10
Stock Exchange
NASDAQ
Ticker
CLRB
According to Cellectar Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -1855.60%. This represents a change of -418.55% compared to the average of 582.52% of the last 4 quarters.
The mean historical ROE of Cellectar Biosciences, Inc. over the last ten years is 168.39%. The current -1855.60% ROE has changed -1201.97% with respect to the historical average. Over the past ten years (40 quarters), CLRB's ROE was at its highest in in the June 2023 quarter at 1.76%. The ROE was at its lowest in in the September 2015 quarter at -273.21%.
Average
168.39%
Median
-87.64%
Minimum
-333.07%
Maximum
2.80%
Discovering the peaks and valleys of Cellectar Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 341.52%
Maximum Annual ROE = 2.80%
Minimum Annual Increase = -1618.72%
Minimum Annual ROE = -333.07%
Year | ROE | Change |
---|---|---|
2023 | 2.80% | -1618.72% |
2022 | -184.43% | 154.26% |
2021 | -72.54% | 169.35% |
2020 | -26.93% | -82.42% |
2019 | -153.15% | 53.40% |
2018 | -99.83% | -20.83% |
2017 | -126.11% | 176.28% |
2016 | -45.65% | -86.30% |
2015 | -333.07% | 341.52% |
2014 | -75.44% | -88.11% |
The current ROE of Cellectar Biosciences, Inc. (CLRB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
848.02%
5-year avg
472.80%
10-year avg
168.39%
Cellectar Biosciences, Inc.’s ROE is less than Diffusion Pharmaceuticals Inc. (0%), greater than Monopar Therapeutics Inc. (-55460.19%), greater than Pulmatrix, Inc. (-110.60%), greater than Tenax Therapeutics, Inc. (-61.78%), greater than Bio-Path Holdings, Inc. (-48.90%), greater than Catalyst Biosciences, Inc. (-2842.40%), less than Capricor Therapeutics, Inc. (1.20%), greater than NextCure, Inc. (-220.26%), greater than Longboard Pharmaceuticals, Inc. (-57.63%), greater than Lumos Pharma, Inc. (-36.93%), greater than ImmunoCellular Therapeutics, Ltd. (-157.99%), less than Bolt Biotherapeutics, Inc. (0%), greater than Applied Molecular Transport Inc. (-61.40%), greater than Aileron Therapeutics, Inc. (-218.56%), greater than Benitec Biopharma Inc. (-47.94%), greater than null (-175.36%),
Company | ROE | Market cap |
---|---|---|
0% | $8.98M | |
-55460.19% | $8.41M | |
-110.60% | $7.30M | |
-61.78% | $12.54M | |
-48.90% | $2.51M | |
-2842.40% | $19.42M | |
1.20% | $132.76M | |
-220.26% | $39.73M | |
-57.63% | $1.36B | |
-36.93% | $30.87M | |
-157.99% | $19.14M | |
0% | $24.78M | |
-61.40% | $11.01M | |
-218.56% | $60.66M | |
-47.94% | $90.98M | |
-175.36% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectar Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cellectar Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Cellectar Biosciences, Inc.'s ROE?
How is the ROE calculated for Cellectar Biosciences, Inc. (CLRB)?
What is the highest ROE for Cellectar Biosciences, Inc. (CLRB)?
What is the 3-year average ROE for Cellectar Biosciences, Inc. (CLRB)?
What is the 5-year average ROE for Cellectar Biosciences, Inc. (CLRB)?
How does the current ROE for Cellectar Biosciences, Inc. (CLRB) compare to its historical average?